Scarica l'app Stockscreener
585.50
1.82%
10.44
Pre-mercato:
588.65
3.15
+0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$575.06
Aprire:
$576.31
Volume 24 ore:
921.07K
Relative Volume:
0.95
Capitalizzazione di mercato:
$60.99B
Reddito:
$14.21B
Utile/perdita netta:
$4.46B
Rapporto P/E:
14.76
EPS:
39.68
Flusso di cassa netto:
$3.56B
1 W Prestazione:
+5.34%
1M Prestazione:
+0.88%
6M Prestazione:
-13.70%
1 anno Prestazione:
-48.94%
Intervallo 1D:
$576.31
$587.67
Intervallo di 1 settimana:
$555.81
$587.67
Portata 52W:
$476.49
$1,165.85
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Harbor Investment Advisory LLC Sells 523 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT - MSN
Integrity Alliance LLC. Makes New $579,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight - Yahoo Finance
Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP - insights.citeline.com
Risk Off: Can Regeneron Pharmaceuticals Inc. expand its profit marginsTrade Performance Summary & AI Based Buy/Sell Signal Reports - خودرو بانک
Regeneron Pharmaceuticals (REGN): Evaluating Valuation Following Breakthrough Phase 3 Allergy Drug Results - simplywall.st
Regeneron (REGN) Rises Amid Positive Obesity Treatment Study - GuruFocus
Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies - uk.finance.yahoo.com
Regeneron, Elf Beauty, Eli Lilly - TradingView
Regeneron Touts Positive Data From Phase 3 StudyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron’s garetosmab shows 90% reduction in bone lesions in FOP patients By Investing.com - Investing.com South Africa
Oruka Therapeutics, Regeneron, natgas companies - TradingView
Regeneron’s garetosmab shows 90% reduction in bone lesions in FOP patients - Investing.com Australia
‘Prolific’ Regeneron won’t stop with phase III FOP data drop - BioWorld MedTech
Regeneron (REGN) Reports Promising Results in Obesity Treatment Trial - GuruFocus
Birch Allergy Market Trends Point to Steady Growth Ahead by 2034, - openPR.com
Regeneron Pharmaceuticals Reports Positive 26-Week Results from Phase 2 COURAGE Trial Combining Semaglutide with Trevogrumab for Obesity Treatment - Quiver Quantitative
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD - MarketScreener
92.6% Fat Loss Achievement: Regeneron's Triple Therapy Outperforms Standard GLP-1 Weight Loss in Phase 2 Trial - Stock Titan
Regeneron's rare bone disorder drug succeeds in late-stage trial - Reuters
Regeneron drug reduces errant bone growth in ultra-rare skeletal condition - statnews.com
Regeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint - MarketScreener
Regeneron announces primary endpoint met in Phase 3 OPTIMA trial - TipRanks
Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study - MarketScreener
Regeneron succeeds in late-stage trial for rare connective disorder therapy - Seeking Alpha
Regeneron's bone disorder treatment succeeds in late-stage trial - Reuters
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation - The Manila Times
Regeneron's genetic disorder treatment meets main goal of late-stage trial - MarketScreener
99% Bone Formation Prevention: Regeneron's Breakthrough Drug Shows Promise for Ultra-Rare FOP Disease - Stock Titan
Woodstock Corp Has $4.21 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
4,105 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by AG2R LA Mondiale Gestion D Actifs - MarketBeat
Focus Partners Wealth Sells 3,238 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
S P Trends: What is Regeneron Pharmaceuticals Inc. s 5 year growth outlookQuarterly Trade Summary & Weekly Top Gainers Alerts - خودرو بانک
Aug Momentum: Is Regeneron Pharmaceuticals Inc trading at a discountJuly 2025 News Drivers & Community Consensus Stock Picks - خودرو بانک
Aug Drivers: Will Regeneron Pharmaceuticals Inc. stock recover after earningsJuly 2025 Sector Moves & Precise Trade Entry Recommendations - خودرو بانک
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - MarketScreener
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - Benzinga
Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial - MSN
Portfolio Recap: What is Regeneron Pharmaceuticals Inc. s 5 year growth outlookJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - خودرو بانک
RMR Wealth Builders Acquires 593 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
GuoLine Advisory Pte Ltd Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Central Pacific Bank Trust Division Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Acadian Asset Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
MBB Public Markets I LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Voleon Capital Management LP - MarketBeat
Surprises Report: Can Regeneron Pharmaceuticals Inc. reach all time highs this year - خودرو بانک
Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight - Yahoo Finance
Custom watchlist performance reports with Regeneron Pharmaceuticals Inc.2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
DOJ Probe and Eylea Sales Pressures Could Be a Game Changer for Regeneron Pharmaceuticals (REGN) - simplywall.st
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? - The Globe and Mail
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.06%
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):